INGREZZA® (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA® (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25 – $1.35 Billion SAN DIEGO, May 4, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for…
News Ticker
- [ June 5, 2023 ] Supervisor, Laboratory – Bio-techne – San Marcos, CA San Diego Biotech Jobs
- [ June 5, 2023 ] UC San Diego Health Recognized for Leadership in Environmental Sustainability News
- [ June 5, 2023 ] Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries News
- [ June 5, 2023 ] Wounded Warrior Project to Team Up with VA to Empower Veterans at Adaptive Sports Clinic News
- [ June 5, 2023 ] Pumping the brakes on autoimmune disease News
Copyright © 2023 Biotech Networks, LLC
